|
Prospector Profile 125-03
|
|
MZT Holdings, Inc. |
NAICS |
325410 |
330 Nevada Street
Newton, MA 02460 |
Description |
Medical Equipment Mfg. |
(617) 928-0820 |
Employees |
75 |
http://www.matritech.com/ |
Revenue |
(mil) |
12.2000 |
|
Income |
(mil) |
-11.9300 |
|
Assets |
(mil) |
5.5100 |
|
Liability |
(mil) |
8.3000 |
|
(for the year ended 2006-12-31) |
|
Category:
Miscellaneous
|
|
Event:
MZT Holdings, Inc., formerly known as Matritech, Inc., announced that it has filed on January 18, 2008, a Certificate of Dissolution with the State of Delaware. In connection with this filing, MZT Holdings closed its stock transfer books and discontinued recording transfers of shares of its common stock, except for transfers by will, intestate succession or operation of law.
|
|
Intellectual Property:
The Company has filed US patent applications and, in certain circumstances, foreign counterparts in selected other countries on developments relating to its nuclear matrix protein technology and to other cancer marker related technologies. It currently has 14 United States patents and 2 pending patent applications on file in the US relating to nuclear matrix proteins and current product line or programs under development. Certain of the US patents provides protection for its NMP22 Test Kit and NMP22 BladderChek Test until 2015. The Company also continues to rely on unpatented proprietary information and trade secrets. [SEC Filing 10-K 03-27-06]
|
|
Description:
MZT Holdings, Inc., formerly known as Matritech, Inc., develops, manufactures, markets, distributes, and licenses cancer diagnostic technologies, products and services.
|
|
Officers:
Stephen D. Chubb (Chair & CEO); David L. Corbet (Pres. & COO); Richard A. Sandberg (VP, CFO, & Treas.); Walter O. Fredericks (Dir.); Judith Kurland (Dir.); Bruce Lehman (Dir.); David B. Musket (Dir.); Jonathan M. Niloff (Dir.); Robert J. Rosenthal (Dir.); T. Stephen Thompson (Dir.); C. William Zadel (Dir.)
|
|
Auditor:
PricewaterhouseCoopers LLP
|
|
Securities:
Common Stock Symbol MZTH.PK; Other OTC;
62,200,272 common shares outstanding as of November 6, 2007.
|
|
|
|
return to main page |
|
|